Penn State College of Medicine Researcher Wins 2018 CureAccelerator Live!

Severe Limb Trauma Clinical Trial Receives Funding to Repurpose Existing Multiple Sclerosis Treatment
Clare Thibodeaux; Winner Dr. John Elfar, Penn State; Barbara Goodman (L to R)
Clare Thibodeaux; Winner Dr. John Elfar, Penn State; Barbara Goodman (L to R)
CHICAGO - Oct. 17, 2018 - PRLog -- Yesterday, John Elfar, MD representing Penn State College of Medicine won Cures Within Reach's 2018 CureAccelerator Live! philanthropic pitch event. CureAccelerator Live! brings together stakeholders from pharma, biotech, academia, medicine, philanthropy and patient groups to showcase repurposing projects in need of funding.  Cures Within Reach is a leading global nonprofit focused on improving patient quality and length of life by leveraging the speed, safety and cost-effectiveness of medical repurposing research. Held in partnership with ExL's Collaborations Addressing Vulnerable Populations Forum in Herndon, Virginia, attendees voted for the winning repurposing clinical trial. The 2018 CureAccelerator Live! event focused on Mid-Atlantic region institutions with projects using repurposed therapies to treat an unmet medical need.

"All the projects presented at CureAccelerator Live! have the potential to quickly create a positive impact for patients with unmet medical needs," said Clare Thibodeaux, PhD, Director of Scientific Affairs at Cures Within Reach. "We congratulate Dr. Elfar on his winning clinical trial, and recognize the outstanding work of the other finalists. The attendees truly had a difficult voting decision to make."

Attendees heard from four clinician-researchers representing three academic medical centers in the Mid-Atlantic region. Dr. Elfar's project, "Repurposing a Drug to Answer the Golden Question in Severe Limb Trauma," will study the ability to diagnose severed vs. crushed nerves in patients suffering from limb trauma using a drug approved for multiple sclerosis patients. If successful, this approach could provide critical information significantly sooner to trauma surgeons treating these patients.  Penn State College of Medicine and Dr. Elfar will receive up to $50,000 in funding from Cures Within Reach to support this research.

"Repurposing research is an important strategy in quickly finding treatments for these patients at risk of losing the use of an arm or leg," stated CureAccelerator Live! winner Dr. Elfar, Penn State's Vice Chair for Research, Department of Orthopaedics and Rehabilitation and the Director, Center for Orthopaedic Research and Translational Science. "I am grateful to Cures Within Reach and its supporters for funding my work, and the work of other researchers like myself, which can make a real difference in patient lives through repurposing."

The other finalists who presented their repurposing projects at CureAccelerator Live! included:

·       Akiva S. Cohen, PhD from the Children's Hospital of Philadelphia presenting "Repurposing a Dietary Therapy for Concussion"
·       Adam Kaplin, MD, PhD from Johns Hopkins University presenting "Repurposing a High-Blood Pressure Drug to Decrease Pediatric Suicide"
·       Mike Wang, ScM from Johns Hopkins University presenting "Repurposing an OTC Cough Medicine as a Rapid-Acting Antidepressant"

Expert Panelists representing pharma, clinicians, academia and a governmental regulatory agency helped attendees make a more informed voting decision.  Panelists included:

·       Leslie Cousens, PhD of AstraZeneca
·       Charbel Moussa, MBBS, PhD of Georgetown University
·       Heather Stone, MPH of the U.S. Food and Drug Administration

Cures Within Reach is grateful for its philanthropic supporters for the 2018 CureAccelerator Live! event, Goldman Philanthropic Partners and the Kahlert Foundation, as well as its other 2018 Global Partners: Horizon Pharma, the Knight Family, Medidata, Takeda Pharmaceuticals, TerSera Therapeutics and Vetter Pharma.

For more information about CureAccelerator Live!, please visit

About Cures Within Reach
Cures Within Reach (CWR) is a US-based global philanthropic leader that improves patient quality and length of life by leveraging the speed, safety and cost-effectiveness of medical repurposing research, driving more treatments to more patients more quickly. CWR catalyzes research to facilitate and validate repurposing opportunities that create clinical impact, and enables and facilitates conversation and action among stakeholders that help transform healthcare through repurposing opportunities. Through repurposing, CWR drives both market impact and health savings to patients and patient groups, from academia/researchers, with payers and the healthcare industry and with support from the government, philanthropy and others. CWR's repurposing research projects have generated "new" treatments in over a dozen indications, making patient impact through off-label use in clinical practice or through a commercialization track.

CWR currently has a global portfolio of 18 repurposing research projects, as well as more than 180 repurposing research projects available for funding in a wide range of diseases on its CureAccelerator® site. Visit or follow CWR via Twitter @CuresWReach, LinkedIn (, YouTube ( or Facebook (

Cures Within Reach
Source: » Follow
Email:*** Email Verified
Location:Chicago - Illinois - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Cures Within Reach PRs
Trending News
Most Viewed
Top Daily News

Like PRLog?
Click to Share